Showing results (291-300 of 297) with videos related to
Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 297 results.
The Lancet. Oncology|September 4, 2025
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Pengfei Shen, Juan Li, et al.Blood|May 14, 2020
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytesRebecca S Hesterberg, Matthew S Beatty, Ying Han, et al.Therapeutic Advances in Medical Oncology|July 24, 2023
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populationsJun Wang, Bicheng Zhang, Ling Peng, et al.Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 TrialCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Journal for Immunotherapy of Cancer|November 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 studyCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Cancer Biology & Medicine|April 9, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alterationHuijing Feng, Yang Xia, Wenxian Wang, et al.Pageof 30